Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Laura Hamill currently holds 6,933 shares of Y-mAbs Therapeutics, Inc. (YMAB), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Laura Hamill has been a net neutral trader of YMAB stock. They have purchased $0 and sold $0 worth of shares.
Laura Hamill's most recent insider trade was on Sep 16, 2025, when they sold 25,080 shares at $0.00 per share.
Laura Hamill serves as Executive at Y-mAbs Therapeutics, Inc. (YMAB). They have executed 13 insider transactions totaling $0 over their tenure at the company.
Laura Hamill holds the position of Executive at Y-mAbs Therapeutics, Inc., where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 7 years and currently hold a stake valued at $0.
Laura Hamill has shown a balanced trading pattern, with $0 in total purchases and $0 in total sales across all transactions. Their most recent activity indicates a balanced approach to trading.
The largest transaction by Laura Hamill was on May 8, 2019, when they sold $231.2K worth of GILD shares. This transaction involved 3,500 shares at $66.07 per share.
Laura Hamill currently owns 6,933 shares of Y-mAbs Therapeutics, Inc. (YMAB), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Laura Hamill's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Laura Hamill has 13 Form 4 filings on record as an insider at Y-mAbs Therapeutics, Inc..
Set alerts for Laura Hamill and 40,000+ other insiders.